Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting pituitary tumors.

Anthony P Heaney1

  • 1Division of Endocrinology and Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, Calif., USA. aheaney@mednet.ucla.edu

Hormone Research
|February 7, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiometabolic Risk Parameters in "Nonfunctioning" Adrenal Incidentalomas: A Systematic Review and Meta-analysis.

The Journal of clinical endocrinology and metabolism·2025
Same author

A Bridge Too Far? Towards Medical Therapy for Clinically Nonfunctioning Pituitary Tumors.

International journal of molecular sciences·2025
Same author

Genetic profiling of synchronous pituitary corticotroph adenomas.

Pituitary·2025
Same author

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.

European journal of endocrinology·2025
Same author

Reduced IGF-1 Levels Following Clomiphene Treatment for Male Hypogonadism.

Journal of the Endocrine Society·2025
Same author

Genetic Profiling of Synchronous Pituitary Corticotroph Adenomas.

Research square·2025
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

New research explores novel therapeutic targets for pituitary tumors, including nuclear receptors and signaling pathways. Pharmacogenomic profiling will guide the use of targeted agents for improved treatment outcomes.

Area of Science:

  • Endocrinology and Oncology
  • Molecular Biology and Pharmacology

Background:

  • Pituitary tumors are common, slow-growing neoplasms often requiring aggressive treatment with surgery and radiation, carrying significant side effects.
  • These tumors arise from dysregulated cellular pathways, presenting numerous molecular targets for therapeutic intervention.
  • Established therapies target membrane receptors like dopamine (D2) and somatostatin receptors.

Purpose of the Study:

  • To review emerging therapeutic targets and novel agents for pituitary tumor management.
  • To highlight the potential of targeting nuclear receptors and intracellular signaling pathways.
  • To discuss the role of pharmacogenomics in guiding personalized pituitary tumor therapy.

Main Methods:

  • Review of current literature on pituitary tumor pathogenesis and therapeutic strategies.

Related Experiment Videos

  • Analysis of the expression and potential targeting of nuclear receptors (estrogen, PPAR, RAR) and signaling molecules (NF-κB, EGFR).
  • Discussion of novel agents, including doxazosin and gene therapy approaches.

    • Main Results:

    • Nuclear receptors are highly expressed in pituitary tumors, with potent ligands becoming available.
    • Novel agents like doxazosin show potential by inhibiting nuclear factor kappa-B (NF-κB) signaling.
    • Targeting the pituitary tumor transforming gene (PTTG) is a potential strategy, though gene therapy faces challenges.

    Conclusions:

    • Advances in understanding pituitary tumor development reveal new therapeutic targets and pathways.
    • Exploration of targeted therapies, informed by pharmacogenomics, is crucial for effective pituitary tumor treatment.
    • Novel agents targeting specific molecular pathways offer promising, safer treatment options.